DYNE THERAPEUTICS ($DYN) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of -$0.76 per share, beating estimates of -$0.78 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $DYN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DYNE THERAPEUTICS Insider Trading Activity
DYNE THERAPEUTICS insiders have traded $DYN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $DYN stock by insiders over the last 6 months:
- JOHN COX (CEO & President) has made 0 purchases and 2 sales selling 5,302 shares for an estimated $90,559.
- DOUGLAS KERR (Chief Medical Officer) has made 0 purchases and 3 sales selling 5,305 shares for an estimated $77,075.
- JOHANNA FRIEDL-NADERER (Chief Commercial Officer) has made 0 purchases and 3 sales selling 1,182 shares for an estimated $16,778.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DYNE THERAPEUTICS Hedge Fund Activity
We have seen 146 institutional investors add shares of DYNE THERAPEUTICS stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 9,714,392 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $122,887,058
- ORBIS ALLAN GRAY LTD added 4,801,928 shares (+inf%) to their portfolio in Q4 2025, for an estimated $93,925,711
- PERCEPTIVE ADVISORS LLC added 2,938,500 shares (+543.7%) to their portfolio in Q4 2025, for an estimated $57,477,059
- VESTAL POINT CAPITAL, LP removed 2,655,000 shares (-95.7%) from their portfolio in Q4 2025, for an estimated $51,931,800
- MARSHALL WACE, LLP removed 2,336,398 shares (-77.5%) from their portfolio in Q4 2025, for an estimated $45,699,944
- CITADEL ADVISORS LLC removed 2,241,811 shares (-65.7%) from their portfolio in Q4 2025, for an estimated $43,849,823
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,898,950 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $37,143,462
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DYNE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $DYN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- Oppenheimer issued a "Outperform" rating on 12/10/2025
- Chardan Capital issued a "Buy" rating on 12/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
To track analyst ratings and price targets for DYNE THERAPEUTICS, check out Quiver Quantitative's $DYN forecast page.
DYNE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $DYN recently. We have seen 8 analysts offer price targets for $DYN in the last 6 months, with a median target of $38.5.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $16.0 on 01/20/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $36.0 on 12/15/2025
- Paul Matteis from Stifel set a target price of $39.0 on 12/11/2025
- Andreas Argyrides from Oppenheimer set a target price of $40.0 on 12/10/2025
- Keay Nakae from Chardan Capital set a target price of $38.0 on 12/09/2025
- Michael Ulz from Morgan Stanley set a target price of $50.0 on 12/09/2025
- Ananda Ghosh from HC Wainwright & Co. set a target price of $60.0 on 12/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
